ASCLS eNewsBytes

• FDA Fully Approves T-Cell Therapy for Advanced Synovial Sarcoma July 14, 2026
  The U.S. Food and Drug Administration has fully approved afamitresgene autoleucel for patients aged 12 years and older with unresectable or metastatic synovial sarcoma who have experienced disease progression after chemotherapy.
• The Future of Type 1 Screening: Will Genetics Replace Autoantibodies? July 14, 2026
  Population-based screening for type 1 diabetes is evolving, with researchers exploring genetic testing as a means to identify at-risk individuals sooner than traditional autoantibody testing. Recent advancements in genomic science allow for the estimation of inherited risk shortly after birth, potentially years before autoantibodies are detectable.
• First Huntington's Disease Patient Dosed with Neural Stem Cell Therapy July 14, 2026
  Huntington's disease therapeutics have achieved a milestone with the first patient receiving an experimental neural stem cell therapy at UCI Health, marking the world’s inaugural human trial of embryonic stem cell-derived neural stem cells for this neurodegenerative disorder.
• New Climate Model May Help Predict Influenza Outbreaks Worldwide July 14, 2026
  Researchers created a susceptible-infected-recovered-susceptible model using influenza data from 81 locations in the Americas, revealing a U-shaped correlation between specific humidity and transmission risk. Increased transmission occurred at both low and high humidity levels in warm conditions, worsened by cooler temperatures.
• FDA Approves Another Over-the-Counter Naloxone Nasal Spray July 14, 2026
  The U.S. FDA has approved Rextovy, an over-the-counter intranasal naloxone product, for emergency opioid overdose treatment, granting nonprescription status to Amphastar Pharmaceuticals.